Revvity Shares Slip Despite Earnings Beat and Raised Profit Outlook

Core Insights - Revvity Inc. shares declined over 2% despite exceeding third-quarter adjusted earnings expectations and raising the full-year profit outlook [1] Financial Performance - The company reported adjusted earnings of $1.18 per share, surpassing the analyst consensus of $1.14 [2] - Revenue for the quarter was $699 million, aligning closely with expectations of $699.39 million, and reflecting a 2% increase from the prior-year quarter [2] - Organic revenue growth was reported at 1% year-over-year [2] Segment Performance - The Diagnostics division experienced a 3% rise in revenue, totaling $356 million [3] - The Life Sciences segment saw a 1% increase in revenue, reaching $343 million [3] - Both segments reported year-over-year declines in adjusted operating margins [3] Future Outlook - Revvity updated its 2025 revenue forecast to a range of $2.83 billion to $2.88 billion, accounting for foreign exchange adjustments [4] - The company maintained its organic growth outlook of 2–4% [4] - Adjusted earnings guidance was raised to $4.90–$5.00 per share, exceeding the consensus estimate of $4.87 [4]